Sona Nanotech Inc.

Equities

SONA

CA83541C1059

Medical Equipment, Supplies & Distribution

Market Closed - Canadian Securities Exchange Other stock markets 03:49:13 2024-05-21 pm EDT			5-day change	1st Jan Change
0.33 ^CAD	+3.12%		0.00%	+37.50%

May. 21	Sona Nanotech Appoints Chief Medical Officer, Files Provisional Conjugation Patent	MT
Apr. 29	Sona Nanotech Inc. Announces Further Results from the Triple Negative Breast Cancer Mice Model Portion of Its Current Research Study At Dalhousie University	CI

Sona Nanotech "building a mountain of data" to support use of proprietary gold nanorods

June 22, 2023 at 09:36 am EDT

(via NewsDirect)

Sona Nanotech Inc. (CSE: SONA, OTCQB: SNANF) CEO David Regan speaks to Thomas Warner from Proactive about his ambitious plans for the Canadian company's proprietary gold nanorods.

He says that Sona Nanotech is currently "building a mountain of data" to support the potential use of its technology in innovative cancer treatments, having recently announced that it had received the third set of results of an independent assessment of its nanorods from the U.S. National Cancer Institute’s Nanotechnology Characterization Laboratory (“NCL”).

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

Latest news about Sona Nanotech Inc.

Sona Nanotech Appoints Chief Medical Officer, Files Provisional Conjugation Patent	May. 21	MT
Sona Nanotech Inc. Announces Further Results from the Triple Negative Breast Cancer Mice Model Portion of Its Current Research Study At Dalhousie University	Apr. 29	CI
Sona Nanotech Provides Interim Results of Dalhousie Study	Apr. 12	MT
Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study	Apr. 12	CI
Sona Nanotech Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	Mar. 29	CI
Sona Nanotech Inc. Appoints Dr. Carman Giacomantonio to its Advisory Board	Mar. 18	CI
Sona Nanotech Inc. Announces Filing of Provisional Patent Application	Mar. 18	CI
Sona Nanotech Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	Feb. 27	CI
Sona Nanotech Inc. Announces Retirement of Michael Gross from the Board of Directors	Jan. 10	CI
Sona Nanotech Inc. announced that it has received CAD 0.75 million in funding	Nov. 26	CI
Sona Nanotech Inc. announced that it has received CAD 0.75 million in funding	Nov. 26	CI
Sona Nanotech Inc. announced that it expects to receive CAD 0.75 million in funding	23-10-17	CI
Sona Nanotech Inc. announced that it expects to receive CAD 0.75 million in funding	23-10-17	CI
Sona Nanotech Inc. Provides Corporate Update on Operating Activities	23-10-12	CI
Sona Nanotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	23-09-28	CI
Sona Nanotech Inc. Announces Innovative Research Initiative to Undertake with Giacomantonio Immuno-Oncology Research Group	23-09-11	CI
Sona Nanotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	23-06-28	CI
Sona Nanotech Inc. Announces First Territorial Patent Grant for Its Proprietary, Toxin-Free Gold Nanorod Manufacturing Process with A Registration in South Korea	23-05-18	CI
Sona Nanotech Inc. Announces Board Changes	23-05-18	CI
Sona Nanotech Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023	23-03-30	CI
Sona Nanotech Inc. completed the acquisition of Siva Therapeutics Inc.	23-03-22	CI
Sona Nanotech Inc. Auditor Raises 'Going Concern' Doubt	23-02-26	CI
Sona Nanotech Inc. Reports Earnings Results for the Full Year Ended October 31, 2022	23-02-26	CI
Sona Nanotech Inc. completed the acquisition of Siva Therapeutics, Inc.	23-02-26	CI
Sona Nanotech Inc. announced that it has received CAD 1.1 million in funding	23-02-23	CI

Chart Sona Nanotech Inc.

Duration

Period

More charts

Company Profile

Sona Nanotech Inc. is a nanotechnology life sciences company that has developed multiple methods for the manufacturing of various types of gold nanoparticles. The Company is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company leverages its core proprietary gold nanorod (GNR) manufacturing technology and laboratory assets to focus on the development of diagnostic tests and biologic reagents, and the advancement of its GNR intellectual property.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-06-24 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
SONA NANOTECH INC.	+37.50%	23.31M
ABBOTT LABORATORIES	-6.46%	180B
MEDTRONIC PLC	+3.39%	112B
BECTON, DICKINSON AND COMPANY	-3.68%	68.53B
DEXCOM, INC.	+5.44%	51.97B
CENCORA, INC.	+5.70%	44.08B
HOYA CORPORATION	+4.54%	42.23B
METTLER-TOLEDO INTERNATIONAL, INC.	+25.42%	32.43B
TERUMO CORPORATION	+14.45%	26.39B
WEST PHARMACEUTICAL SERVICES, INC.	-4.29%	24.97B

Other Medical Equipment, Supplies & Distribution